Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

879 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Mas JL, et al. Among authors: zuber m. N Engl J Med. 2017 Sep 14;377(11):1011-1021. doi: 10.1056/NEJMoa1705915. N Engl J Med. 2017. PMID: 28902593 Free article. Clinical Trial.
Reversible cerebral angiopathy: efficacy of nimodipine.
Zuber M, Touzé E, Domigo V, Trystram D, Lamy C, Mas JL. Zuber M, et al. J Neurol. 2006 Dec;253(12):1585-8. doi: 10.1007/s00415-006-0269-x. Epub 2006 Oct 24. J Neurol. 2006. PMID: 17063316
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators. Bousser MG, et al. Cerebrovasc Dis. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16. Cerebrovasc Dis. 2009. PMID: 19372653 Free article. Clinical Trial.
Primary angiitis of the central nervous system: description of the first fifty-two adults enrolled in the French cohort of patients with primary vasculitis of the central nervous system.
de Boysson H, Zuber M, Naggara O, Neau JP, Gray F, Bousser MG, Crassard I, Touzé E, Couraud PO, Kerschen P, Oppenheim C, Detante O, Faivre A, Gaillard N, Arquizan C, Bienvenu B, Néel A, Guillevin L, Pagnoux C; French Vasculitis Study Group and the French NeuroVascular Society. de Boysson H, et al. Among authors: zuber m. Arthritis Rheumatol. 2014 May;66(5):1315-26. doi: 10.1002/art.38340. Arthritis Rheumatol. 2014. PMID: 24782189
Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
Alessi MC, Gaudin C, Grosjean P, Martin V, Timsit S, Mahagne MH, Larrue V, Sibon I, Zuber M, Brouns R, Montaner J, Castellanos M, Donazzolo Y, Cho TH, Suissa L, Mechtouff L, Derex L, Suchon P, Mezzapesa A, Nighoghossian N. Alessi MC, et al. Among authors: zuber m. Cerebrovasc Dis. 2016;42(5-6):404-414. doi: 10.1159/000447722. Epub 2016 Jul 8. Cerebrovasc Dis. 2016. PMID: 27387478
Tumor-Like Presentation of Primary Angiitis of the Central Nervous System.
de Boysson H, Boulouis G, Dequatre N, Godard S, Néel A, Arquizan C, Detante O, Bloch-Queyrat C, Zuber M, Touzé E, Bienvenu B, Aouba A, Guillevin L, Naggara O, Pagnoux C; French Vasculitis Study Group. de Boysson H, et al. Among authors: zuber m. Stroke. 2016 Sep;47(9):2401-4. doi: 10.1161/STROKEAHA.116.013917. Epub 2016 Jul 28. Stroke. 2016. PMID: 27470990
Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke.
Leys D, Hommet Y, Jacquet C, Moulin S, Sibon I, Mas JL, Moulin T, Giroud M, Sagnier S, Cordonnier C, Medeiros de Bustos E, Turc G, Ronzière T, Bejot Y, Detante O, Ouk T, Mendyk AM, Favrole P, Zuber M, Triquenot-Bagan A, Ozkul-Wermester O, Montoro FM, Lamy C, Faivre A, Lebouvier L, Potey C, Poli M, Hénon H, Renou P, Dequatre-Ponchelle N, Bodenant M, Debruxelles S, Rossi C, Bordet R, Vivien D; OPHELIE investigators and the STROKAVENIR network. Leys D, et al. Among authors: zuber m. Neurology. 2016 Dec 6;87(23):2416-2426. doi: 10.1212/WNL.0000000000003399. Epub 2016 Nov 4. Neurology. 2016. PMID: 27815401 Clinical Trial.
AMOBES (Active Mobility Very Early After Stroke): A Randomized Controlled Trial.
Yelnik AP, Quintaine V, Andriantsifanetra C, Wannepain M, Reiner P, Marnef H, Evrard M, Meseguer E, Devailly JP, Lozano M, Lamy C, Colle F, Vicaut E; AMOBES Group. Yelnik AP, et al. Stroke. 2017 Feb;48(2):400-405. doi: 10.1161/STROKEAHA.116.014803. Epub 2016 Dec 22. Stroke. 2017. PMID: 28008092 Clinical Trial.
879 results